CardioFocus places AFib system at 100th hospital
Photo | Courtesy
The HeartLight Excalibur Balloon used with the new HeartLight® X3 System.
Marlborough-based medtech CardioFocus said Tuesday its flagship system to treat an irregular heartbeat is now available at 100 hospitals around the world.
That system, the HeartLight Endoscopic Ablation System, has been used to treat more than 6,500 patients in the United States, Europe and Japan, the company said.
The device treats a condition known as atrial fibrillation, or AFib, an irregularity of the heart that can cause blood clots, stroke and other complications.
CardioFocus President and Chief Commercial Officer Omari Bouknight said the company has seen a surge in demand for the system and the number of hospitals offering the technology has more than doubled over the last year.
"AFib is a widespread, debilitating condition that requires advanced solutions to improve outcomes,” he said. “By collaborating with leading institutions and physicians in the field, we will make this revolutionary treatment available to a greater number of patients worldwide."
Several iterations of the device have received both U.S. and foreign clearance beginning in 2016 with the U.S. Food and Drug Administration. Two years later, the FDA approved the Excalibur Balloon as part of the Heartlight system.
The HeartLight X3 System was cleared for European use in March.
Last month, the company said it completed a $55 million round of financing to accelerate the commercial introduction of the Heartlight systems both in the U.S. and abroad.
WBJ Web Partners
Most Recent
Most Recent
0 Comments